1.646.889.1200|info@lifescipublicrelations.com

Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB

//Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB

Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB

In a recent interview with Daniel de Boer, CEO of ProQR, Rare Disease Report® discussed the company’s new RNA therapy, QR-313, for the treatment of dystrophic epidermolysis bullosa (DEB).

By | 2018-06-14T16:45:57-04:00 May 25th, 2018|News|Comments Off on Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.